Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

A modular multi-Basket trial to improve personalized medicine in cancer patients Recruiting

2024-514238-19-00 Subjects with advanced solid tumour 2018-03-28
Pre-operative capecitabine, oxaliplatin, docetaxel and atezolizumab in gastric cancer (PANDA) Recruiting

2024-519075-26-00 Primary resectable, histologically confirmed gastric or 2018-02-27
Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonit… Recruiting

2024-513526-27-00 secondary or quaternary peritonitis 2018-02-23
Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma: phase 2 trial evaluating the efficacy and the toxicit… Recruiting

2024-516810-39-00 Adjuvant therapy after salvage surgery of high risk rec 2018-02-13
A multicenter trial where patients with CML stop medication a second time. Recruiting

2024-515409-25-00 Chronic myeloid leukemia 2018-01-11
FASTERCC Recruiting

2024-515413-18-00 Metastatic renal cell carcinoma (mRCC) 2017-12-22
Hydroxychloroquine treatment for Recurrent Pregnancy Loss: a randomized double-blind placebo-controlled trial Recruiting

2024-515579-36-00 Recurrent Pregnancy Loss 2017-04-12
The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders Recruiting

2024-511842-38-00 Neurodegenerative disorders with Tau-pathology; includi 2017-04-10
Phase II Study of Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in Patients with Locally Advanced/ Metastatic Squamous Cell Ca… Recruiting

2024-513637-20-00 Locally Advanced/Metastatic Squamous Cell Carcinoma of 2017-03-24
Nordic Pancreatic Cancer Trial (NORPACT) – 1 Recruiting

2024-517719-65-00 Resectable pancreatic head cancer 2017-02-01
Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial Recruiting

2024-513314-35-00 Adenocarcinoma of the Colon or rectosigmoid (considered 2017-01-20
Desferal administration to improve the impaired reaction to hypoxia in diabetes (DESIRED) - A randomised, double-blind, placebo-controlled, … Recruiting

2024-519562-48-00 The study will investigate the effect of deferoxamine o 2017-01-12
A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiothe… Recruiting

2024-515678-29-00 Patients with metastatic tumours (colorectal, non-small 2016-11-15
Evaluation of Lymphadenectomy and Chemotherapy TIP (paclitaxel, ifosfamide and cisplatin) on Inguinal Lymph Nodes in Squamous Cell Carcinoma… Recruiting

2024-512827-36-00 Penis carcinoma 2016-10-17
DRUP trial Recruiting

2023-509152-33-00 Advanced solid tumor 2016-07-25
Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with progressive advanced Well-differentiated gastro-intestinal (G… Recruiting

2024-513200-34-00 advanced progressive gastro-intestinal or lung carcinoi 2016-04-19
Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer… Recruiting

2024-516221-31-00 Stage IV colorectal cancer 2016-04-19
GRAALL2014 Recruiting

2024-516103-16-00 Acute Lymphoblastic Leukemia (ALL) in younger adults (1 2015-12-04
Long-term follow-up of the WAS gene therapy study Recruiting

2024-512680-31-00 Treatment of Wiskott-Aldrich Syndrome 2014-10-29
Evaluation of the effectiveness of genome analysis as a therapeutic decision tool for patients with metastatic breast cancer. Recruiting

2024-518002-41-00 Patients with metastatic breast cancer in 1st or 2nd li 2014-04-07
MOST Plus (My Own Specific Treatment) - A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of… Recruiting

2023-510566-27-00 Advanced / Metastatic cancers 2014-02-27
MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial Recruiting

2024-515626-92-00 recurrent/progressive medulloblastoma, ependymoma and a 2013-10-18
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant Mesothelioma Recruiting

2024-511841-20-00 unresectable pleural or peritoneal malignant mesothelio 2013-09-23
Conservative treatment of patients with retinoblastoma Recruiting

2024-517275-21-00 Retinoblastoma 2012-02-20